Adulteration of hypoglycemic products: the silent threat

Background. The growing tendency toward the adulteration of hypoglycemic products in the market to increase the seller’s profits, the increased promotions of such products by unscrupulous promoters, and the higher rate of consumption by diabetic patients in the community all of these represent an al...

Full description

Bibliographic Details
Main Authors: Raniah I. Alnaser, Fawaz A. Alassaf, Mohammed N. Abed
Format: Article
Language:English
Published: Amaltea Medical Publishing House 2023-12-01
Series:Romanian Journal of Medical Practice
Subjects:
Online Access:https://rjmp.com.ro/articles/2023.4/RJMP_2023_4_Art-04.pdf
_version_ 1797257168699785216
author Raniah I. Alnaser
Fawaz A. Alassaf
Mohammed N. Abed
author_facet Raniah I. Alnaser
Fawaz A. Alassaf
Mohammed N. Abed
author_sort Raniah I. Alnaser
collection DOAJ
description Background. The growing tendency toward the adulteration of hypoglycemic products in the market to increase the seller’s profits, the increased promotions of such products by unscrupulous promoters, and the higher rate of consumption by diabetic patients in the community all of these represent an alarm for serious health problems that could be fatal and have a potential threat to public health when using them. Aim. This review aims to attract the attention of the researchers to the hazardous clinical outcomes of adulterated hypoglycemic products and encourage them to do further studies analyzing the compositions of the available hypoglycemic products. Results. Based on the obtained data from the latest studies, the available hypoglycemic products have undeclared and banned anti-diabetic agents that lead to serious side effects. Conclusion. The popularity and abundance of adulterated hypoglycemic products in the market that are claimed to be effective for type 2 diabetes mellitus (Ty2DM) are hazardous to public health and have significant clinical outcomes due to their undeclared anti-diabetic agents which could be lethal to diabetic patients.
first_indexed 2024-03-07T22:48:15Z
format Article
id doaj.art-205bd55ca8284b35a2e90b0a9f4dc8b4
institution Directory Open Access Journal
issn 1842-8258
2069-6108
language English
last_indexed 2024-04-24T22:33:21Z
publishDate 2023-12-01
publisher Amaltea Medical Publishing House
record_format Article
series Romanian Journal of Medical Practice
spelling doaj.art-205bd55ca8284b35a2e90b0a9f4dc8b42024-03-19T12:53:34ZengAmaltea Medical Publishing HouseRomanian Journal of Medical Practice1842-82582069-61082023-12-0118420220510.37897/RJMP.2023.4.4Adulteration of hypoglycemic products: the silent threatRaniah I. Alnaser0Fawaz A. Alassaf1Mohammed N. Abed2Nineveh Health Directorate, Mosul, Nineveh province, Iraq; Department of Pharmacology and Toxicology, College of Pharmacy, University of Mosul, Mosul, Nineveh province, IraqDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Mosul, Mosul, Nineveh province, IraqDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, Nineveh province, IraqBackground. The growing tendency toward the adulteration of hypoglycemic products in the market to increase the seller’s profits, the increased promotions of such products by unscrupulous promoters, and the higher rate of consumption by diabetic patients in the community all of these represent an alarm for serious health problems that could be fatal and have a potential threat to public health when using them. Aim. This review aims to attract the attention of the researchers to the hazardous clinical outcomes of adulterated hypoglycemic products and encourage them to do further studies analyzing the compositions of the available hypoglycemic products. Results. Based on the obtained data from the latest studies, the available hypoglycemic products have undeclared and banned anti-diabetic agents that lead to serious side effects. Conclusion. The popularity and abundance of adulterated hypoglycemic products in the market that are claimed to be effective for type 2 diabetes mellitus (Ty2DM) are hazardous to public health and have significant clinical outcomes due to their undeclared anti-diabetic agents which could be lethal to diabetic patients.https://rjmp.com.ro/articles/2023.4/RJMP_2023_4_Art-04.pdfanti-diabeticshypoglycemic productsadulterated hypoglycemic products
spellingShingle Raniah I. Alnaser
Fawaz A. Alassaf
Mohammed N. Abed
Adulteration of hypoglycemic products: the silent threat
Romanian Journal of Medical Practice
anti-diabetics
hypoglycemic products
adulterated hypoglycemic products
title Adulteration of hypoglycemic products: the silent threat
title_full Adulteration of hypoglycemic products: the silent threat
title_fullStr Adulteration of hypoglycemic products: the silent threat
title_full_unstemmed Adulteration of hypoglycemic products: the silent threat
title_short Adulteration of hypoglycemic products: the silent threat
title_sort adulteration of hypoglycemic products the silent threat
topic anti-diabetics
hypoglycemic products
adulterated hypoglycemic products
url https://rjmp.com.ro/articles/2023.4/RJMP_2023_4_Art-04.pdf
work_keys_str_mv AT raniahialnaser adulterationofhypoglycemicproductsthesilentthreat
AT fawazaalassaf adulterationofhypoglycemicproductsthesilentthreat
AT mohammednabed adulterationofhypoglycemicproductsthesilentthreat